PR Newswire: news distribution, targeting and monitoring
2014

Drug Discovery Outsourcing: World Market 2013-2023

Share with Twitter Share with LinkedIn

NEW YORK, Jan. 3, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Drug Discovery Outsourcing: World Market 2013-2023

http://www.reportlinker.com/p0595029/Drug-Discovery-Outsourcing-World-Market-2013-2023.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development

Report Details

How much revenue can drug discovery outsourcing generate? Our new report shows you See what the future holds for outsourcing early-stage drug development. There is rising demand for those services. Visiongain's updated report gives you revenue predictions to 2023, showing you data, trends, opportunities and commercial prospects.

Our study is your guide to the potential of those pharmaceutical services. That analysis lets you assess forecasted sales at overall world market, submarket and national level. You see outlooks for the outsourced drug discovery industry and market and its participants.

Forecasts and other analyses to help you find growth opportunities

In our report you find revenue forecasting to 2023, historical data, growth rates and market shares. Also, you see qualitative analysis (SWOT and STEP), business news, outlooks and developmental trends (R&D). You receive 64 tables, 46 charts and two research interviews.

We show where sales growth can occur. You investigate the most lucrative areas of that contract research segment, assessing industry trends, dynamics and outlooks. Its technologies hold great promise for service providers and the pharma industry.

You can stay ahead in knowledge, benefiting your research and analyses. The following sections show what you find in our new study.

You see prospects for the world market and submarkets

Along with analyses of the overall world market, you see revenue forecasting of four outsourcing submarkets at world level. We show data from 2011 to 2023: • Chemical services• Biological services• Lead optimisation• Lead identification and screening.

With our investigation you gain business research and analysis with individual sales predictions and discussions. You find analysis of competition, as well as commercial drivers and restraints. See what's likely to achieve the most success.

You can win competitive advantages by understanding the trends, opportunities and challenges facing contract research organisations (CROs) in drug discovery.

Our work also breaks the overall world forecast into leading national markets.

What are the prospects in leading regions and countries? Developments worldwide will influence the market, especially rising demand in emerging countries - China, India and others. There are many opportunities for CRO service providers and pharma clients.

In our study you find individual revenue forecasts to 2023 for eleven national markets:• US• Japan• Germany, France, UK, Italy and Spain (EU5)• Brazil, Russia, India and China (BRIC nations).

See what's likely to happen. There will be high growth in established markets and developing countries - especially to 2017 - our analyses show. You find areas with highest potential. Also, you investigate reasons for revenue growth.

What issues will affect outsourced drug discovery? Our report discusses issues and events affecting early-stage drug development from 2012 onwards:

• Progress in target identification, validation, chemistry, biology and ADMET screening

• Cost reductions, outsourcing efficiency and improved turnaround times

• Strategic partnering and differentiation of research activities provision

• Biologics, biosimilars and orphan drug development.

Also, you find coverage of these aspects:• Regional expansion, competition and CRO consolidation• Niche CROs and virtual pharmaceutical companies• Technology transfer and intellectual property (IP)• Competition from public-private partnerships• Technological developments - instruments, biomarkers, genomics and proteomics.

See what the future holds. You investigate technological, commercial, economic and political matters, with emphasis on the competitive landscape and business outlooks.

Leading companies and market value in 2015 What will happen next? Overall world revenue for that market area will reach $16.6bn in 2015, our work forecasts. We predict strong revenue growth from 2012 to 2023.

Our study gives you analyses of these CROs:• Quintiles• Charles River Laboratories• Covance• Evotec• PPD.

We also give profiles of these service vendors, and discuss other companies too:

• Albany Molecular Research

• Aptuit

• Cyprotex

• Domainex

• Galapagos

• GenScript

• WIL Research Laboratories

• WuXi AppTec.

Also, you see interviews with two companies. You see what's happening. This decade, many opportunities will arise - our report shows you the commercial possibilities.

Seven ways Drug Discovery Outsourcing: World Market 2013-2023 helps you

In particular, then, our investigation gives you the following knowledge on the topic:• Forecasted revenues to 2023 for the overall world market and 4 submarkets - you discover the industry's future prospects• Market forecasting to 2023 for US, Japan, Germany, France, UK, Spain, Italy, Brazil, Russia, India and China - you see national sales outlooks• Profiles of 13 leading companies - you hear about CROs' activities, recent results, strategies and outlooks• Opinions on the sector - you read our interviews with leaders in industry• Competition and opportunities influencing sales - you see what affects the future• Discussions of what stimulates and restrains the industry and market - you assess trends, drivers and restraints• Prospects for established organisations and those seeking to enter the sector - you see factors and outlooks for success.

Benefit from our analyses, gaining information found nowhere else

That work gives independent analysis from our primary and secondary research. You receive business intelligence found only in our study, seeing where prospects are lucrative and growth is likely.

With our report you are less likely to fall behind in knowledge or miss opportunity. See how our work could benefit your research, analyses and decisions, saving you time and getting you recognition for commercial insight.

You find prospects to 2023 for drug discovery services by ordering now Visiongain's study is for everyone needing analysis of the industry and market for outsourced drug development. You find data, trends and predictions. Please ask for our report now.

Visiongain is a trading partner with the US Federal GovernmentCCR Ref number: KD4R6

Table of Contents

1. Executive Summary1.1 Review of the Global Drug Discovery Outsourcing Market1.2 Aims, Scope and Format of Report1.3 Research and Analysis Methods

2. Drug Discovery Outsourcing: An Introduction

2.1 Outsourcing in the Pharmaceutical and Biotechnology Industries

2.1.1 Outsourcing Drug Discovery

2.2 Reasons for Outsourcing Drug Discovery Operations

2.2.1 Strategic Outsourcing vs. Tactical Outsourcing

2.2.2 Benefits of Outsourcing

2.2.3 Cost Pressures and Declining R&D Budgets

2.2.4 Outsourcing and Focus on Core Competencies

2.2.5 Outsourcing to Improve Efficiency and Reduce Time-to-Market

2.2.6 Forming Strategic Partnerships with Big Pharma

2.3 The Drug Discovery Process - What Can be Outsourced?

2.4 A New Model for Drug Development?

2.5 Academic Laboratories - Early Drug Discovery Research

2.6 Quality of Service is Important for CROs

2.7 Drug Discovery Outsourcing by the Pharmaceutical Industry

3. Leading Companies Offering Drug Discovery Services3.1 Introduction3.2 Key Attributes of a Successful Contract Research Organisation (CRO)3.2.1 Competitive Cost Structure3.2.2 Strong Scientific Skill Set3.2.3 Excellent Turnaround Times and Good Communication3.2.4 Intellectual Property Security3.2.5 Good Working Relationships are Essential3.3 Drug Discovery Service Providers, 20113.4 Albany Molecular Research, Inc (AMRI)3.4.1 Drug Discovery at AMRI3.4.2 Discovery Collaboration Record3.5 Aptuit3.5.1 Aptuit INDiGO - Accelerated Drug Development Programme3.5.2 Strategic Partnership With Laurus Labs3.6 Charles River Laboratories3.6.1 Revenue Analysis 2006-20113.6.2 Early Stage Restructuring3.7 Covance3.7.1 Revenue Analysis 2009-20113.7.2 Refocusing Early-Stage Efforts3.7.3 Strategic Alliance Experience3.8 Cyprotex - ADMET Service Provider3.9 Domainex - Full Service Drug Discovery Provider3.10 Evotec - Discovery Alliances and Development Partnerships3.10.1 Action Plan 2016 - Leadership in Drug Discovery Solutions3.11 Galapagos (GLPG)3.11.1 Galapagos - Recent Activity3.12 GenScript3.12.1 GenScript - Outsourcing Activity3.13 PPD - A Leading CRO3.13.1 Revenue Analysis 2009-20113.13.2 Strategic Alliances and Private Merger3.13.3 Expansion in Asia3.13.4 PPD and BioDuro3.14 Quintiles - Largest Biopharmaceutical Services Company3.14.1 Quintiles - Acquisition of Advion Bioanalytical Labs3.14.2 Quintiles - New Developments3.15 WIL Research Laboratories3.16 WuXi AppTec - A Leading Chinese CRO3.16.1 Revenue Analysis 2006-20113.16.2 WuXi's Strategic Partnerships and Other Recent Developments

4. Global Drug Discovery Outsourcing Market 2013-2023

4.1 The Global Drug Discovery Outsourcing Market 2011

4.2 Global Drug Discovery Outsourcing: Market Forecast 2013-2023

4.3 Global Chemistry Services Outsourcing Market 2013-2023

4.3.1 Global Chemistry Services Outsourcing 2011

4.3.1.1 Custom Synthesis

4.3.1.2 Building Blocks

4.3.1.3 Process Research

4.3.1.4 Libraries

4.3.2 Global Chemistry Services Outsourcing: Market Forecast 2013-2023

4.4 Global Biology Services Outsourcing Market 2013-2023

4.4.1 Global Biology Services Outsourcing 2011

4.4.1.1 Target Identification

4.4.1.2 Target Validation

4.4.2 Global Biology Services Outsourcing: Market Forecast 2013-2023

4.5 Global Lead Optimisation Outsourcing Market 2013-2023

4.5.1 Global Lead Optimisation Outsourcing 2011

4.5.1.1 ADMET Screening

4.5.2 Global Lead Optimisation: Market Forecast 2013-2023

4.6 Global Lead Identification and Screening Outsourcing Market 2013-2023

4.6.1 Global Lead Identification and Screening Outsourcing 2011

4.6.1.1Lead Identification

4.6.2 Global Lead Identification and Screening Outsourcing: Market Forecast 2013-2023

5. Leading National Markets for Drug Discovery Outsourcing 2013-20235.1 Supply and Demand for Drug Discovery Outsourcing Services5.2 The Drug Discovery Outsourcing Market: Regional Breakdown 20115.3 The US Drug Discovery Outsourcing Market Forecast 2013-20235.4 Leading Western European (EU5) Countries: Market Forecast 2013-20235.4.1 The German Drug Discovery Outsourcing Market Forecast 2013-20235.4.2 The UK Drug Discovery Outsourcing Market Forecast 2013-20235.4.3 The French Drug Discovery Outsourcing Market Forecast 2013-20235.4.4 The Italian Drug Discovery Outsourcing Market Forecast 2013-20235.4.5 The Spanish Drug Discovery Outsourcing Market Forecast 2013-20235.5 The Japanese Drug Discovery Outsourcing Market Forecast 2013-20235.6 Emerging BRIC Nations 2013-20235.6.1 BRIC Nations Will Lead Market Growth5.6.2 The Brazilian Drug Discovery Outsourcing Market Forecast 2013-20235.6.3 The Russian Drug Discovery Outsourcing Market Forecast 2013-20235.6.4 The Indian Drug Discovery Outsourcing Market Forecast 2013-20235.6.5 The Chinese Drug Discovery Outsourcing Market Forecast 2013-2023

6. Drug Discovery Outsourcing: World Market Trends 2013-2023

6.1 SWOT Analysis of the Market 2013-2023

6.1.1 Drivers and Restraints for Drug Discovery Outsourcing 2013-2023

6.2 Market Strengths

6.2.1 Cost Reductions Will Drive Drug Discovery Operations

6.2.2 Outsourcing Efficiency Improves Turnaround Times

6.3 Market Weaknesses

6.3.1 Some CROs Offer Service Ranges Without Clear Market Differentiation

6.3.2 Adverse Effects of Reducing R&D Spending

6.4 Market Opportunities and Threats

6.4.1 Trends in Drug Development

6.4.2 Orphan Drug Development

6.4.3 Biologics and Biosimilars

6.4.4 CRO Expansion

6.4.4.1 An Increasingly Competitive Market

6.4.4.2 Regional Expansion

6.4.5 Increased CRO Consolidation and Niche CROs

6.4.6 Outsourcing Strategy Depends on Company Size

6.4.7 Virtual Pharmaceutical Companies

6.4.8 Technology Transfer and Intellectual Property Protection

6.4.9 Competition from Public-Private Partnerships

6.4.10 Pharma Resource Sharing Could Restrain CRO Growth

6.5 STEP Analysis for Drug Discovery Outsourcing 2013-2023

6.5.1 Social Factors

6.5.1.1 Increased Healthcare Demands

6.5.1.2 Good Communication is Vital

6.5.2 Technological Developments

6.5.2.1 Biomarkers as a Tool for Drug Development

6.5.2.2 Technological Advances in Genomic and Proteomic Instrumentation

6.5.3 Economic Pressures

6.5.3.1 Cutting Back Pharma R&D

6.5.3.2 Growth in Strategic Partnering

6.5.4 Political Issues

6.5.4.1 Quality Practices in Basic Biomedical Research (QPBR) and Good Laboratory Practice (GLP)

6.5.4.2 Global Harmonisation of Regulatory Policies: The ICH

7. Opinions from Our Survey: Research Interviews7.1 Interview with Dr Raj (SB) Rajur, Chairman & CEO, CreaGen Biosciences7.1.1 Thoughts on Current State of the Market7.1.2 Drug Discovery Services at CreaGen Biosciences7.1.3 Challenges Facing Pharma and Biotech R&D7.1.4 Thoughts on Therapeutic Areas and Niche CROs7.1.5 National Markets for Drug Discovery Outsourcing7.1.6 Drivers and Restraints for Market Growth7.2 Interview with Dr Mario Polywka, Chief Operating Officer, Evotec7.2.1 CROs and R&D Outsourcing7.2.2 Drug Discovery Outsourcing Services7.2.3 Thoughts on Drug Discovery Trends7.2.4 Driving Drug Discovery Outsourcing

8. Conclusions

8.1 Robust Growth for Drug Discovery Outsourcing 2013-2023

8.2 Outsourcing in Asia Will Continue to Grow

8.3 Key Indications for Research Will Drive Growth

8.4 Opportunities for Strategic Partnering and Niche CROs Will Continue

List of Tables

Table 1.1 Currency Exchange Rates, 2011Table 2.1 Indication of Functions Outsourced in the Different Stages of the Drug R&D Process, 2012Table 3.1 AMRI Revenue ($m), 2007-2011Table 3.2 AMRI Drug Discovery Portfolio, 2012Table 3.3 Selected Services Provided by Charles River Laboratories, 2012Table 3.4 Charles River Laboratories Revenue ($bn), 2006-2011Table 3.5 Charles River Laboratories Revenue ($bn) by Business Segment, 2009-2011Table 3.6 Covance Revenue ($bn) by Segment, 2009-2011Table 3.7 Covance Revenue ($bn) by Service, 2009-2011Table 3.8 Selected Cyprotex Partners, 2012Table 3.9 Cyprotex Revenue ($m), AGR (%), 2009-2011Table 3.10 Selected Examples of Domainex's CollaborationsTable 3.11 Evotec Revenue ($m), AGR (%), 2007-2011Table 3.12 Evotec Alliances, AGR (%), 2008-2011Table 3.13 Evotec Action Plan 2016 - Leadership in Drug Discovery SolutionsTable 3.14 Galapagos: Selected Pipeline Activity, 2012Table 3.15 Galapagos Alliances, 2006-2012Table 3.16 Galapagos Revenues ($m), AGR (%), 2008-2011Table 3.17 Select GenScript Services, 2012Table 3.18 PPD Revenue ($bn), 2009-2011Table 3.19 WuXi AppTec: Pharmaceutical Laboratory Services, 2012Table 3.20 WuXi AppTec Revenue ($bn), 2006-2011Table 4.1 Global Drug Discovery Outsourcing Revenue Forecasts by Segment ($m), AGR (%), CAGR (%), 2011-2017Table 4.2 Global Drug Discovery Outsourcing Revenue Forecasts by Segment ($m), AGR (%), CAGR (%), 2017-2023Table 4.3 Drug Discovery Outsourcing: World Market Shares by Segment (%), 2011, 2017 & 2023Table 4.4 Chemistry Services Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017Table 4.5 Chemistry Services Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023Table 4.6 Biology Services Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017Table 4.7 Biology Services Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023Table 4.8 Lead Optimisation Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017Table 4.9 Lead Optimisation Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023Table 4.10 Lead Identification and Screening Revenue Forecast ($m), AGR (%), CAGR (%), 2011-2017Table 4.11 Lead Identification and Screening Revenue Forecast ($m), AGR (%), CAGR (%), 2017-2023Table 5.1 National Drug Discovery Outsourcing Revenue Forecasts ($m), AGR (%), CAGR (%), 2011-2017Table 5.2 National Drug Discovery Outsourcing Revenue Forecasts ($m), AGR (%), CAGR (%), 2017-2023Table 5.3 Drug Discovery Outsourcing: World Market Shares by Region (%), 2011, 2017 & 2023Table 5.4 The US Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2011-2017Table 5.5 The US Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2017-2023Table 5.6 EU5 Drug Discovery Outsourcing Revenue Forecasts ($m), AGR (%), CAGR (%), 2011-2017Table 5.7 EU5 Drug Discovery Outsourcing Revenue Forecasts ($m), AGR (%), CAGR (%), 2017-2023Table 5.8 Drug Discovery Outsourcing: EU5 Market Shares by Region (%), 2011, 2017 & 2023Table 5.9 The German Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2011-2017Table 5.10 The German Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2017-2023Table 5.11 The UK Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2011-2017Table 5.12 The UK Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2017-2023Table 5.13 The French Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2011-2017Table 5.14 The French Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2017-2023Table 5.15 The Italian Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2011-2017Table 5.16 The Italian Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2017-2023Table 5.17 The Spanish Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2011-2017Table 5.18 The Spanish Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2017-2023Table 5.19 The Japanese Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2011-2017Table 5.20 The Japanese Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2017-2023Table 5.21 The Brazilian Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2011-2017Table 5.22 The Brazilian Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2017-2023Table 5.23 The Russian Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2011-2017Table 5.24 The Russian Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2017-2023Table 5.25 The Indian Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2011-2017Table 5.26 The Indian Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2017-2023Table 5.27 The Chinese Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2011-2017Table 5.28 The Chinese Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2017-2023Table 6.1 Drug Discovery Outsourcing: SWOT Analysis, 2013-2023Table 6.2 NIH Biomarker Definitions, 2012Table 8.1 Global Drug Discovery Outsourcing Forecast ($m), AGR (%), CAGR (%), 2011-2023

List of Figures

Figure 2.1 Selected Tasks Outsourced in the Pharmaceutical Industry, 2012

Figure 2.2 Typical Stages of the Drug Development Cycle

Figure 3.1 AMRI Revenue ($m), 2007-2011

Figure 3.2 Charles River Laboratories Revenue ($bn), 2006-2011

Figure 3.3 Charles River Laboratories Revenue (%) by Business Segment, 2011

Figure 3.4 Covance Revenue (%) by Segment, 2011

Figure 3.5 Covance Revenue ($bn) by Service, 2009-2011

Figure 3.6 Cyprotex Revenue ($m), 2009-2011

Figure 3.7 Evotec Revenue ($m) and Alliances, 2008-2011

Figure 3.8 Evotec Regional Revenue Share (%), 2011

Figure 3.9 Galapagos Revenue ($m), 2008-2011

Figure 3.10 Galapagos Revenue (%) by Segment, 2011

Figure 3.11 PPD Revenue ($bn), 2009-2011

Figure 3.12 WuXi AppTec Revenue ($bn), 2006-2011

Figure 4.1 Global Drug Discovery Outsourcing Revenue Forecast ($m), 2011-2017

Figure 4.2 Global Drug Discovery Outsourcing Revenue Forecast ($m), 2017-2023

Figure 4.3 Drug Discovery Outsourcing: World Market Shares by Segment (%), 2011

Figure 4.4 Drug Discovery Outsourcing: World Market Shares by Segment (%), 2017

Figure 4.5 Drug Discovery Outsourcing: World Market Shares by Segment (%), 2023

Figure 4.6 Chemistry Services Revenue Forecast ($m), 2011-2017

Figure 4.7 Chemistry Services Revenue Forecast ($m), 2017-2023

Figure 4.8 Biology Services Revenue Forecast ($m), 2011-2017

Figure 4.9 Biology Services Revenue Forecast ($m), 2017-2023

Figure 4.10 Lead Optimisation Revenue Forecast ($m), 2011-2017

Figure 4.11 Lead Optimisation Revenue Forecast ($m), 2017-2023

Figure 4.12 Lead Identification and Screening Revenue Forecast ($m), 2011-2017

Figure 4.13 Lead Identification and Screening Revenue Forecast ($m), 2017-2023

Figure 5.1 Drug Discovery Outsourcing: World Market Shares by Region (%), 2011

Figure 5.2 Drug Discovery Outsourcing: World Market Shares by Region (%), 2017

Figure 5.3 Drug Discovery Outsourcing: World Market Shares by Region (%), 2023

Figure 5.4 The US Drug Discovery Outsourcing Forecast ($m), 2011-2023

Figure 5.5 The EU5 Drug Discovery Outsourcing Forecast ($m), 2011-2023

Figure 5.6 Drug Discovery Outsourcing: EU5 Market Shares by Country (%), 2011

Figure 5.7 The German Drug Discovery Outsourcing Forecast ($m), 2011-2023

Figure 5.8 The UK Drug Discovery Outsourcing Forecast ($m), 2011-2023

Figure 5.9 The French Drug Discovery Outsourcing Forecast ($m), 2011-2023

Figure 5.10 The Italian Drug Discovery Outsourcing Forecast ($m), 2011-2023

Figure 5.11 The Spanish Drug Discovery Outsourcing Forecast ($m), 2011-2023

Figure 5.12 The Japanese Drug Discovery Outsourcing Forecast ($m), 2011-2023

Figure 5.13 The Brazilian Drug Discovery Outsourcing Forecast ($m), 2011-2023

Figure 5.14 The Russian Drug Discovery Outsourcing Forecast ($m), 2011-2023

Figure 5.15 The Indian Drug Discovery Outsourcing Forecast ($m), 2011-2023

Figure 5.16 The Chinese Drug Discovery Outsourcing Forecast ($m), 2011-2023

Figure 6.1 Drug Discovery Outsourcing: Drivers, 2013-2023

Figure 6.2 Drug Discovery Outsourcing: Restraints, 2013-2023

Figure 8.1 Global Drug Discovery Outsourcing Forecast by Segment ($m), 2011-2023

Companies Listed

AbbottAbCROAccugenixAdvion Bioanalytical LabsAdvion BioService Albany Molecular Research, Inc (AMRI)American Cancer SocietyAndromeda BiotechApredicaAptuit Aptuit LaurusArgentaArk Therapeutics ArQule Associação Brasileira de CROs (Abracro) AstraZenecaBayerBehrman CapitalBeijing Genomics InstituteBioDuroBioDuro Biologics BioFocusBioPontis Alliance Boehringer IngelheimBoston CollegeBristol-Myers SquibbBundesverband Medizinischer Auftragsinstitute (BVMA)Caprion Proteomics Carlyle GroupCatalent Pharma Solutions CerebriconCharles River Laboratories CHDI Foundation ChemBridgeChemDivCompound Focus CovanceCreaGen BiosciencesCrucell CyprotexDeveloGenDiscovery Partners International DomainexDow AgroSciencesDow Chemical Company ElanEli LillyEvotecEvotec BioSystems AGExcel PharmaStudies Fidelity Growth Partners India (FGPI)Food and Drug Administration (US FDA)Furiex PharmaceuticalsGalapagosGenentechGenScriptGlaxoSmithKline (GSK)GlycoformGreat Lakes Chemical CorporationHarvard Medical SchoolHellman & FriedmanHorizon Hypha DiscoveryICON InpharmaticaInSphero InVentiv HealthJohnson & Johnson (J&J) Janssen PharmaceuticaJanssen Pharmaceutical GroupKinaxoKnopp Biosciences Laurus Labs LonzaMAB DiscoveryMassachusetts General Hospital MedImmuneMerck & Co.MicrosoftMidwest BioResearch MilliporeNational Institutes of Health (NIH)Northeastern UniversityNovartisOno Pharmaceutical Oxford Asymmetry InternationalParexelPeking Union Lawke Biomedical DevelopmentPfizerPharmaceutical Product Development (PPD) Pharmaceutical Research and Manufacturers of America (PhRMA) PharminoxPiedmont Research CenterPPDPRA InternationalProSkeliaProStrakanProteome SciencesProteros Biostructutres GmbH (Proteros) ProtonMediaQuintilesRocheRules-Based Medicine (RBM)SamsungSanofiSareumServierShionogi Sirius AnalyticalSolvo BiotechnologySouthwestern Medical CenterSwiss Pharma Contract Sygnature DiscoverySYN|thesis Med ChemTaijitu BiologicsTakedaTeva The Dow Chemical CompanyThe European CRO Federation (EUCROF)The Institute of Cancer ResearchThe International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)The Organization for Economic Cooperation and Development (OECD)TibotecTRAC MicrobiologyTransGenicUCB University of ManchesterVitualScopicsWellcome TrustWIL Research LaboratoriesWorld Health Information Science Consultants (WHISCON)World Health Organization (WHO)World Trade Organization (WTO)WuXi AppTecWuXi PharmaTech

To order this report:Drug_Discovery_and_Development Industry: Drug Discovery Outsourcing: World Market 2013-2023

Nicolas Bombourg

Reportlinker

Email: nicolasbombourg@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

Featured Video

Journalists and Bloggers

Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.

View and download archived video content distributed by MultiVu on The Digital Center.

Share with Twitter Share with LinkedIn
 

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

 
 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

 
 

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.

 

Online Member Center

Not a Member?
Click Here to Join
Login
Search News Releases
Advanced Search
Search
  1. PR Newswire Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
  5. Send a News Release